Evidence map›Paper›PMID 38527936›Full record

ArticleAngewandte Chemie (International ed. in English)2024

A Lipopeptidomimetic of Transcriptional Activation Domains Selectively Disrupts the Coactivator Med25 Protein-Protein Interactions.

Olivia N Pattelli, Estefanía Martínez Valdivia, Matthew S Beyersdorf, Clint S Regan, Mónica Rivas, Katherine A Hebert, Sofia D Merajver, Tomasz Cierpicki, Anna K Mapp

Open access · bronzeAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Olivia N PattelliLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Estefanía Martínez ValdiviaLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Matthew S BeyersdorfLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Clint S ReganLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Mónica RivasLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Katherine A HebertDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Sofia D MerajverDepartment of Internal Medicine, Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Tomasz CierpickiProgram in Chemical Biology, University of Michigan, Ann Arbor, MI 48109, USA.
Anna K MappLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-0791-8327
University of Michigan · USWashtenaw Community College · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Probing transcriptional activation at the molecular level - Equipment SupplementR35GM136356 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANNA K. MAPP · 2020 to 2026
$3.3M
NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA046592NIGMS NIH HHS GM136356NIGMS NIH HHS R35 GM136356
6 · The paper itself

Abstract

Short amphipathic peptides are capable of binding to transcriptional coactivators, often targeting the same binding surfaces as native transcriptional activation domains. However, they do so with modest affinity and generally poor selectivity, limiting their utility as synthetic modulators. Here we show that incorporation of a medium-chain, branched fatty acid to the N-terminus of one such heptameric lipopeptidomimetic (LPPM-8) increases the affinity for the coactivator Med25 >20-fold (Ki >100 μM to 4 μM), rendering it an effective inhibitor of Med25 protein-protein interactions (PPIs). The lipid structure, the peptide sequence, and the C-terminal functionalization of the lipopeptidomimetic each influence the structural propensity of LPPM-8 and its effectiveness as an inhibitor. LPPM-8 engages Med25 through interaction with the H2 face of its activator interaction domain and in doing so stabilizes full-length protein in the cellular proteome. Further, genes regulated by Med25-activator PPIs are inhibited in a cell model of triple-negative breast cancer. Thus, LPPM-8 is a useful tool for studying Med25 and mediator complex biology and the results indicate that lipopeptidomimetics may be a robust source of inhibitors for activator-coactivator complexes.

Indexed as

Mediator ComplexTranscriptional ActivationHumansPeptidesProtein BindingMED25 protein, humanMediator ComplexPeptidesCoactivatorLipopeptideMed25Protein–protein interaction inhibitorTranscription factor

Identifiers

PMID38527936
PMCPMC11134611
OpenAlexW4393196292

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.